SCYNEXIS (135) Stock Overview

A biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. More details

135 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Revenue is forecast to grow 20.21% per year

Earnings have grown 16.7% per year over the past 5 years

Risk Analysis

Shares are highly illiquid

Earnings are forecast to decline by an average of 20.6% per year for the next 3 years

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

135 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW444,159 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

444,159 investors already sharing narratives

View all narratives

SCYNEXIS, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for SCYNEXIS
Historical stock prices
Current Share Price	US$4.05
52 Week High	US$7.62
52 Week Low	US$3.82
Beta	1.11
1 Month Change	-7.12%
3 Month Change	n/a
1 Year Change	-46.94%
3 Year Change	-83.56%
5 Year Change	-90.05%
Change since IPO	-99.18%

Recent updates

Shareholder Returns

	135	DE Pharmaceuticals	DE Market
7D	-8.5%	-1.3%	-2.2%
1Y	-46.9%	41.8%	3.4%

Return vs Industry: 135 underperformed the German Pharmaceuticals industry which returned 40.8% over the past year.

Return vs Market: 135 underperformed the German Market which returned 4% over the past year.

Price Volatility

Is 135's price volatile compared to industry and market?
135 volatility
135 Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	4.9%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	12.3%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: 135's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 135's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1999	18	David Angulo	www.scynexis.com

SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections.

SCYNEXIS, Inc. Fundamentals Summary

How do SCYNEXIS's earnings and revenue compare to its market cap?
135 fundamental statistics
Market cap	€41.70m
Earnings (TTM)	-€8.86m
Revenue (TTM)	€16.64m

2.4x

P/S Ratio

-4.5x

P/E Ratio

Is 135 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
135 income statement (TTM)
Revenue	US$19.22m
Cost of Revenue	US$0
Gross Profit	US$19.22m
Other Expenses	US$29.45m
Earnings	-US$10.23m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-1.03
Gross Margin	100.00%
Net Profit Margin	-53.26%
Debt/Equity Ratio	0%

How did 135 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/14 11:35
End of Day Share Price	2026/09/14 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

SCYNEXIS, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brian Kemp Dolliver	Brookline Capital Markets
Corey Davis	Canaccord Genuity
Liisa Bayko	Citizens JMP Securities, LLC

SCYNEXIS (135) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

SCYNEXIS, Inc. Competitors

Biofrontera

MPH Health Care

Cantourage Group

PEPTONIC medical

Price History & Performance

Recent News & Updates

SCYNEXIS, Inc. Announces CFO Changes, Effective September 9, 2026

Second quarter 2026 earnings released: EPS: US$0.63 (vs US$1.11 loss in 2Q 2025)

SCYNEXIS, Inc. Initiates Phase 1 Study of SCY-770 for Treatment of Autosomal Dominant Polycystic Kidney Disease

Insufficient new directors

SCYNEXIS, Inc., Annual General Meeting, Jun 25, 2026

SCYNEXIS, Inc. announced that it expects to receive $40.019125 million in funding from Squadron Capital Management Llc, Propel Bio Partners LLC, Great Point Partners, LLC, Adage Capital Management, L.P.

Recent updates

SCYNEXIS, Inc. Announces CFO Changes, Effective September 9, 2026

Second quarter 2026 earnings released: EPS: US$0.63 (vs US$1.11 loss in 2Q 2025)

SCYNEXIS, Inc. Initiates Phase 1 Study of SCY-770 for Treatment of Autosomal Dominant Polycystic Kidney Disease

Insufficient new directors

SCYNEXIS, Inc., Annual General Meeting, Jun 25, 2026

SCYNEXIS, Inc. announced that it expects to receive $40.019125 million in funding from Squadron Capital Management Llc, Propel Bio Partners LLC, Great Point Partners, LLC, Adage Capital Management, L.P.

SCYNEXIS, Inc. Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247

Scynexis, Inc. Receives Fda Qualified Infectious Disease Product and Fast Track Designations for SCY-247

SCYNEXIS, Inc. Completes Transfer of Brexafungerp New Drug Application to Gsk

SCYNEXIS, Inc. Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of Its Second-Generation Fungerp (SCY-247)

SCYNEXIS Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Rule

Scynexis, Inc. Resumes Patient Dosing in Phase 3Io Study

SCYNEXIS, Inc., Annual General Meeting, Jun 25, 2025

SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023)

First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023)

New major risk - Revenue and earnings growth

SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024

SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases

Full year 2023 earnings released: EPS: US$1.40 (vs US$1.47 loss in FY 2022)

Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.62 loss in 3Q 2022)

Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc

SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology

SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance

Investor sentiment improves as stock rises 17%

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$2.56 (vs US$0.31 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.17 loss in 1Q 2022)

Forecast breakeven date moved forward to 2023

Forecast to breakeven in 2025

Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis

Insufficient new directors

Third quarter 2022 earnings released: US$0.62 loss per share (vs US$0.023 loss in 3Q 2021)

SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health

SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022

SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022

SCYNEXIS, Inc. Announces CEO Changes

SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study

Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.064 profit in 2Q 2021)

SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022

SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting

SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME

Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update

Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole

SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections

SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022

SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting

SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022

No longer forecast to breakeven

Insufficient new directors

SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million.

SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections

No longer forecast to breakeven

SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections

Insufficient new directors

Forecast to breakeven in 2024

SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis

Scynexis, Inc. Announces Peer-Reviewed Publication of Results

Scynexis, Inc. Announces U.S. Availability of BREXAFEMME®